

GENTA INC DE/  
Form 8-K  
February 23, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): February 23, 2007

**GENTA INCORPORATED**

(Exact Name of Registrant  
as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19635**

(Commission File Number)

**33-0326866**

(IRS Employer Identification No.)

**200 Connell Drive  
Berkeley Heights, NJ**

(Address of Principal Executive  
Offices)

**07922**

(Zip Code)

**(908) 286-9800**

(Registrant's Telephone Number, Including Area Code)

---

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On February 23, 2007, Genta Incorporated, (the Company), issued a press release announcing preliminary results from a Phase 2 study of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced prostate cancer. This randomized open-label trial was conducted by the European Organisation for Research and Treatment of Cancer (EORTC). Dr. Cora N. Sternberg, from the San Camillo Forlanini Hospital in Rome, Italy, presented the data this afternoon at *The Prostate Cancer Symposium*, a joint meeting of the American Society of Clinical Oncology, the Society of Urologic Oncology and the American Society for Therapeutic Radiology and Oncology, which is being held this week in Orlando, Florida.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release of the Company dated February 23, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: February 23, 2007

By: /s/ RICHARD J. MORAN

Name: Richard J. Moran

Title: Senior Vice President, Chief  
Financial Officer and  
Corporate Secretary

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description**

**Sequentially  
Numbered Page**

99.1

Press Release of the Company dated February 23, 2007